Press release
Harvard Bioscience Announces First Quarter 2024 Financial Results
Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024.
Press release
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m.
Press release
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately
Press release
Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference
HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be
Press release
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
Q4 Revenues of $28.2 million Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million, adjusted operating income of $ 3.3 million Strong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverage HOLLISTON,
Press release
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics HOLLISTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the
Press release
Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.